# Internal Review - Round 1

**Reviewer:** Claude Code (Internal)
**Paper:** State Insulin Copay Cap Laws and Working-Age Diabetes Mortality
**Date:** 2026-02-04

---

## PART 1: CRITICAL REVIEW

### 1. Format Check

- **Length:** Approximately 31 pages of main text (before appendix). Exceeds 25-page minimum.
- **References:** Adequate coverage of DiD methodology (Callaway-Sant'Anna, Goodman-Bacon, Sun-Abraham, Rambachan-Roth), insulin pricing literature, and health economics.
- **Prose:** All major sections written in paragraphs. No bullet-point issues except acceptable use in methods (estimation aggregation types).
- **Section depth:** Each section has multiple substantive paragraphs.
- **Figures:** All 6 main-text figures present with visible data, proper axes and labels.
- **Tables:** All tables populated with real numbers. No placeholders detected.

### 2. Statistical Methodology

- **Standard errors:** All coefficients report SEs in parentheses or in dedicated SE columns. PASS.
- **Significance testing:** P-values and significance stars reported. PASS.
- **Confidence intervals:** 95% CIs reported in robustness table and inference table. PASS.
- **Sample sizes:** N reported in all regression tables. PASS.
- **DiD with staggered adoption:** Uses Callaway-Sant'Anna (primary), TWFE as benchmark, Sun-Abraham as robustness. Never-treated controls used. Goodman-Bacon decomposition reported. PASS.
- **Wild cluster bootstrap:** Reported with Webb weights, 9,999 replications. PASS.
- **HonestDiD:** Both relative-magnitudes AND smoothness/FLCI approaches reported. PASS.

### 3. Identification Strategy

- Parallel trends assumption discussed and tested via event study with 20 pre-treatment years.
- No anticipation assumption justified by policy mechanism.
- Placebo tests (cancer, heart disease) support design validity — all null as expected.
- COVID-19 sensitivity addressed through multiple approaches (year dummies, death rate controls, excluding 2020-2021).
- Vermont exclusion justified by data suppression; sensitivity to classification reported.

**Concern:** The placebo tests show large standard errors (heart disease SE=6.872, cancer SE=5.376) relative to point estimates. While the null findings are expected, the large SEs mean the placebos have limited power to detect spurious effects. This should be acknowledged.

### 4. Literature

Coverage is adequate. The paper cites foundational DiD methodology papers, insulin pricing literature, and health outcomes research. The contribution relative to Keating et al. (2024) is clearly articulated.

### 5. Writing Quality

- Prose is well-structured with logical flow from motivation through results to interpretation.
- The dilution algebra framework (Section 3) is a strength — it clearly explains why the working-age restriction matters.
- Active voice used throughout. Sentences are varied in length and structure.
- Technical terms explained on first use.

### 6. Issues Identified

a) **Table 5 (heterogeneity) observation counts:** The three columns show N=731, 777, 774, which sum to 2,282. This exceeds the full sample N=1,142 because each column includes all never-treated states plus a different subset of treated states. This overlap should be noted more explicitly in the table notes to prevent confusion.

b) **Wild bootstrap SE notation:** The "--" for wild bootstrap SE in Tables 4 and 12 could be misread as missing data. Should use a footnote marker with explanation.

c) **COVID year indicators specification yields identical point estimate to baseline:** The paper should note that year fixed effects already absorb COVID year indicators, explaining the identical coefficients.

## PART 2: CONSTRUCTIVE SUGGESTIONS

1. The paper would benefit from a brief power analysis subsection that explicitly computes the MDE for the working-age panel and compares it to the all-ages MDE, making the power improvement concrete.

2. Consider discussing heterogeneity by time-since-treatment more explicitly — the acute (DKA prevention) vs. chronic (complication reduction) pathways predict different temporal patterns.

3. The conclusion could more explicitly discuss what would be needed to detect effects if they exist: longer post-treatment horizons, individual-level data, or alternative outcomes (DKA hospitalizations, insulin adherence).

## OVERALL ASSESSMENT

**Strengths:**
- Novel contribution addressing the primary criticism of the parent paper (outcome dilution)
- Rigorous methodology with appropriate modern DiD estimators
- Comprehensive robustness battery
- Well-written with clear narrative arc

**Weaknesses:**
- Minor notation issues in tables (wild bootstrap SE, heterogeneity N overlap)
- Short post-treatment horizon limits ability to detect chronic pathway effects
- CDC WONDER API fallback to scaled proxy data (acknowledged in text)

DECISION: MINOR REVISION
